Minimal Change Disease and Focal Segmental Glomerulosclerosis

  • Philip David Mason


Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are considered together since, although their aetiology may be different, they share clinical features and are, at least initially, managed in a similar way.


Nephrotic Syndrome Plasma Exchange Glomerular Basement Membrane Focal Segmental Glomerulosclerosis Minimal Change Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Nephrol Dial Transplant. 1997;12(3):418–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis. 1997;30(5):621–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004;44(5):815–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Rood IM, Deegens JK, Wetzels JF. Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice. Nephrol Dial Transplant. 2012;27(3):882–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, et al. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol. 2009;20(2):260–6.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Bakker WW, van Dael CM, Pierik LJ, van Wijk JA, Nauta J, Borghuis T, et al. Altered activity of plasma hemopexin in patients with minimal change disease in relapse. Pediatr Nephrol. 2005;20(10):1410–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Ali AA, Wilson E, Moorhead JF, Amlot P, Abdulla A, Fernando ON, et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation. 1994;58(7):849–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Abdel-Hafez M, Shimada M, Lee PY, Johnson RJ, Garin EH. Idiopathic nephrotic syndrome and atopy: is there a common link? Am J Kidney Dis. 2009;54(5):945–53.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Clement LC, Avila-Casado C, Mace C, Soria E, Bakker WW, Kersten S, et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med. 2011;17(1):117–22.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med. 2012;366(17):1648–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Kemper MJ, Wolf G, Muller-Wiefel DE. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med. 2001;344(5):386–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours JF, et al. Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol. 1998;9(9):1709–15.PubMedGoogle Scholar
  13. 13.
    Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334(14):878–83.PubMedCrossRefGoogle Scholar
  14. 14.
    McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(11):2115–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952–60.PubMedCrossRefGoogle Scholar
  16. 16.
    D’Agati VD. Pathobiology of focal segmental glomerulosclerosis: new developments. Curr Opin Nephrol Hypertens. 2012;21(3):243–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS. Long-term outcome for children with minimal-change nephrotic syndrome. Lancet. 1985;1(8425):368–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis. 1995;25(4):534–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978;13(2):159–65.Google Scholar
  21. 21.
    Fuiano G, Comi N, Magri P, Sepe V, Balletta MM, Esposito C, et al. Serial morphometric analysis of sclerotic lesions in primary “focal” segmental glomerulosclerosis. J Am Soc Nephrol. 1996;7(1):49–55.PubMedGoogle Scholar
  22. 22.
    Border WA. Distinguishing minimal-change disease from mesangial disorders. Kidney Int. 1988;34(3):419–34.PubMedCrossRefGoogle Scholar
  23. 23.
    Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Eur J Pediatr. 1993;152(4):357–61.PubMedCrossRefGoogle Scholar
  24. 24.
    Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124(2):747–57.PubMedCrossRefGoogle Scholar
  25. 25.
    Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Lancet. 1988;1(8582):380–3.Google Scholar
  26. 26.
    Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2007(4):CD001533.Google Scholar
  27. 27.
    Trompeter RS, Evans PR, Barratt TM. Gonadal function in boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods. Lancet. 1981;1(8231):1177–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft fur Padiatrische Nephrologie. Arch Dis Child. 1987;62(11):1102–6.Google Scholar
  29. 29.
    Niaudet P, Broyer M, Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin Nephrol. 1991;35 Suppl 1:S31–6.PubMedGoogle Scholar
  30. 30.
    Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet. 1991;337(8757):1555–7.Google Scholar
  31. 31.
    Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(6):1308–15.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int. 1986;29(6):1215–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Tse KC, Lam MF, Yip PS, Li FK, Choy BY, Lai KN, et al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol Dial Transplant. 2003;18(7):1316–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Melocoton TL, Kamil ES, Cohen AH, Fine RN. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am J Kidney Dis. 1991;18(5):583–8.PubMedGoogle Scholar
  35. 35.
    Korbet SM. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol. 1998;9(7):1333–40.PubMedGoogle Scholar
  36. 36.
    Banfi G, Moriggi M, Sabadini E, Fellin G, D’Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol. 1991;36(2):53–9.PubMedGoogle Scholar
  37. 37.
    Siegel NJ, Gaudio KM, Krassner LS, McDonald BM, Anderson FP, Kashgarian M. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int. 1981;19(3):454–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Tarshish P, Tobin JN, Bernstein J, Edelmann Jr CM. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1996;10(5):590–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Meyrier A, Noel LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int. 1994;45(5):1446–56.PubMedCrossRefGoogle Scholar
  40. 40.
    Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999;56(6):2220–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Keith DS. Therapeutic apheresis rescue mission: recurrent focal segmental glomerulosclerosis in renal allografts. Semin Dial. 2012;25(2):190–2.PubMedCrossRefGoogle Scholar
  42. 42.
    Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis. 1994;23(4):574–81.PubMedGoogle Scholar
  43. 43.
    Gonzalez E, Ettenger R, Rianthavorn P, Tsai E, Malekzadeh M. Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant. 2011;15(5):495–501.PubMedCrossRefGoogle Scholar
  44. 44.
    Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83(3):511–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Vester U, Kranz B, Zimmermann S, Hoyer PF. Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol. 2003;18(7):661–4.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Philip David Mason
    • 1
  1. 1.Oxford Kidney UnitThe Churchill HospitalOxfordUK

Personalised recommendations